Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway, being investigated in a Phase 1a/1b trial in patients with solid tumors. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at www.curis.com.
Location: United States, Massachusetts, Lexington
Member count: 51-200
Founded date: 2000
Investors 1
Date | Name | Website |
14.05.2021 | EW Healthc... | ewhealthca... |
Mentions in press and media 24
Date | Title | Description | Source |
07.10.2021 | Curis : Announces New Preclinical Data Highlighting the Pote... | LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company f... | marketscre... |
03.08.2021 | Curis Reports Second Quarter 2021 Financial Results | LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company... | prnewswire... |
25.06.2021 | Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® I... | LEXINGTON, Mass., June 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology compan... | prnewswire... |
11.06.2021 | Curis Announces Positive Updated Data from Ongoing Phase 1/2... | LEXINGTON, Mass., June 11, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology compan... | prnewswire... |
01.06.2021 | Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A... | LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company... | prnewswire... |
12.05.2021 | Curis Reports First Quarter 2021 Financial Results | LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company... | prnewswire... |
12.05.2021 | Curis Reports Updated Data in Two Abstracts for CA-4948 Acce... | LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company... | prnewswire... |
19.04.2021 | Curis Receives FDA Orphan Drug Designation for CA-4948 for t... | LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology compa... | prnewswire... |
16.03.2021 | Curis Reports Fourth Quarter and Year-End 2020 Financial Res... | LEXINGTON, Mass., March 16, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology compa... | prnewswire... |
10.03.2021 | Curis Announces Abstract for CA-4948 Accepted for Presentati... | LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology compa... | prnewswire... |
Show more